Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon alfa-2d
- Development stage
- Discontinued
- Lead developer
- Wellcome
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular, Intravenous, Intralesional
01
Overview
Interferon alfa-2d is a recombinant type I interferon produced using recombinant DNA technology. It belongs to the family of alpha interferons, which act as **cytokines** and have both antiviral and antineoplastic properties. The drug binds to the type I interferon receptor (comprising interferon alpha/beta receptor 1 and 2 subunits) and **activates the JAK-STAT signaling pathway**, resulting in the transcription of multiple interferon-stimulated genes. These genes upregulate host innate immune responses, enhance the function of cytotoxic T cells and natural killer cells, boost antigen presentation, and induce enzymes that inhibit viral replication. The agent is used for the **treatment of certain malignancies and viral infections**, similar to other alfa interferons. Its main difference from interferon alfa-2a and alfa-2b lies in a few amino acid substitutions, which do not notably alter its pharmacodynamic profile. The original developer was Wellcome (now GSK).
- Brand names
- Wellferon
- Other names
- interferon alpha-2dinterferon alpha-2d recombinantIFN-α2dIFN-alfa-2dIFN-alfa2dIFN-alfa 2d
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on interferon alfa-2d.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon alfa-2d.